With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
IQV — frequently asked questions
Is IQVIA Holdings Inc. overvalued?
In our latest published analysis dated 2026-10-03, IQV looks meaningfully overvalued. The price recorded at analysis is USD 258 versus our fair value of USD 215; the high endpoint is presented separately as potential value of USD 256. That implies roughly 16.7% downside to fair value at that date.
Our latest published report, analyzed 2026-10-03, gives IQV a fair value of USD 215 and a potential value of USD 256. The conclusion is triangulated across multiple valuation models and weighted by reliability for IQVIA Holdings Inc.'s archetype; it is a dated research output, not a live price.
Should I buy IQV now?
Our latest published rating for IQV, analyzed 2026-10-03, is Reduce. IQVIA Holdings Inc. looks meaningfully overvalued at the analysis-date price of USD 258 versus fair value of USD 215; potential value is USD 256. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for IQV?
The dedicated bear-case section in our report analyzed 2026-10-03 documents IQVIA Holdings Inc.'s material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is IQV's rating?
Our latest published rating for IQV, analyzed 2026-10-03, is Reduce, with a published moat assessment of 7.8/10 (Narrow). It reflects our fair value of USD 215, the potential value of USD 256, and the price recorded at analysis (USD 258).
Accelerated enterprise adoption of AI-enabled analytics and real-world health data within Technology & Analytics Solutions ($6,626M FY2025 revenue), alongside a strong rebound in clinical trial bookings ($8,896M R&D Solutions revenue), could expand consolidated operating margins toward 14.70%, lifting annual free cash flow above $2,500M and driving valuation toward Potential value of $256.27.
Main risk
IQVIA faces scheduled debt maturities of $7,413M over FY2026-FY2028 out of $16,174M in total debt against an elevated 5.24% risk-free rate and 6.41% pre-tax borrowing cost.
We rate IQVIA Holdings Inc. as Reduce. The stock was priced at $258.21 on October 2, 2026, trading 19.99% above our Fair value of $215.19 as heavy debt refinancing requirements and clinical wage pressures outweigh steady revenue compounding.4
We rate IQVIA Holdings Inc. as Reduce. For an everyday investor, this rating means the stock is priced above its fundamental worth and existing positions should be trimmed or avoided rather than accumulated.4
The stock was priced at $258.21 on October 2, 2026. Our analysis establishes a Fair value of $215.19 per share, indicating -16.66% implied return (the report-date price trades at a 19.99% premium to fair value). The report-date price also exceeds our Potential value of $256.27 per share, offering an unfavorable risk-reward profile.4
The primary risk that could further impair value is IQVIA's substantial debt load of $16,174M, with $7,413M maturing across the next three years during an era of elevated interest rates where the risk-free rate is 5.24% and borrowing rates sit at 6.41%. Refinancing these obligations at higher rates would expand annual interest costs, eroding net income and halting share repurchases. Investors would observe this risk through gross margin dropping below 32.00% or net debt rising above 6.00x operating cash flow.2,4,6
The main reason the business can generate value is its strong dual-engine franchise. High-margin software subscriptions and proprietary healthcare data in Technology & Analytics Solutions ($6,626M revenue in FY2025) combined with outsourced trial scale in R&D Solutions ($8,896M revenue) generate $2,051M in annual free cash flow. If software adoption accelerates and operating margins expand toward 14.70%, value per share could reach Potential value of $256.27, though this remains below the report-date price.5,6,7
Global Clinical Research Scale
IQVIA operates the world's leading outsourced clinical trial infrastructure, generating $8,896M in FY2025 revenue with strong multi-year biopharma backlog and customer retention.7
Proprietary Healthcare Data and Analytics
Technology & Analytics Solutions provides $6,626M in recurring software and real-world health data revenues, underpinning $2,051M in annual free cash flow.5,7
High Customer Switching Costs in Clinical Trial Execution
Biopharmaceutical sponsors face immense regulatory, procedural, and operational switching barriers once trial protocols, clinical investigator sites, and patient recruitment workflows are contracted with IQVIA. R&D Solutions accounts for $8,896M or 54.5% of FY2025 revenue, supported by multi-year backlog and global presence across the Americas ($7,745M), EMEA ($5,185M), and APAC ($3,380M),,.7
House recommendation
Reduce: IQVIA trades at a 19.99% premium to our Fair value of $215.19, as refinancing obligations on $16,174M of debt and clinical cost pressures outweigh steady top-line growth.4
Company overview
Financial pressures driving the need for increased efficiency. Product portfolios for life sciences companies have shifted toward specialty products with lower peak market sales potential than traditional primary care medicines. IQVIA HOLDINGS INC. provides a range of medical services and scientific strategy to help biopharmaceutical companies plan and transition from the clinical trial setting to commercialization.
Effective January 1, 2026, its reportable segments consist of Commercial Solutions and Research & Development Solutions. See Note 20 to its audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K for further details. In certain of the jurisdictions noted above, the Company operates through more than one legal entity, each of which has different open years subject to examination. The table above presents the open years subject to examination for the most material of the legal entities in each jurisdiction.
Under a combined macro and operational stress test where biopharma sponsor funding delays trial starts and refinancing occurs at elevated market yields, IQVIA faces simultaneous top-line deceleration and margin compression. If venture capital funding for early-stage biotechnology contracts further, Phase II/III trial cancellations would cut consolidated revenue growth from the consensus expectation of 6.79% in FY2026 toward 1.79%. Simultaneously, ongoing clinical research site coordinator wage inflation and pass-through cost escalation threaten to reduce consolidated operating margins by 300 bps from 13.38% in FY2025 to 10.38%. With $16,174M in total debt and $7,413M maturing across the next three years, refinancing at prevailing pre-tax debt costs of 6.41% would add $100M-$200M in annual interest expense, halting share repurchases ($1,244M in FY2025) and lowering free cash flow generation from $2,051M, depressing intrinsic valuation toward the downside anchor of $187.84.
IQVIA Holdings Inc. possesses a narrow economic moat underpinned by two complementary structural advantages: high customer switching costs in its clinical research organization business and valuable intangible data assets within commercial health analytics. In R&D Solutions ($8,896M revenue in FY2025, or 54.5% of total revenue), biopharmaceutical clients contract complex, multi-year Phase I through IV clinical trials across dozens of countries. Transferring an active trial protocol to an alternative provider involves immense regulatory validation hurdles, clinical investigator re-training, and site disruption, locking in clients across multi-year development timelines across the Americas ($7,745M), EMEA ($5,185M), and APAC ($3,380M),,.
In Technology & Analytics Solutions ($6,626M revenue, 40.6% share), IQVIA maintains an extensive proprietary repository of longitudinal prescription and patient data. These data streams are deeply embedded into the standard operating procedures of pharmaceutical commercialization, market access, and post-market safety surveillance. Because these information assets cannot be easily synthesized or replicated without decades of pharmacy and healthcare clearinghouse partnerships, client renewal rates remain exceptionally high, supporting steady cash generation of $2,654M in operating cash flow and $2,051M in ,.
The highlighted cell is Fair value when every assumption sits at its base level ($215.19). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $1.7B after modeled reinvestment of $367.3M, with terminal value at 79.0% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to , reinvestment, or resets materially.
Upgrade the rating; Review contract backlog conversion and monitor whether margin expansion is durable before considering any change in portfolio allocation.
Trigger: Consolidated revenue and diluted earnings exceeding consensus expectations driven by accelerating net bookings in R&D Solutions and expanding operating margins in Technology and Analytics Solutions.
A comprehensive beat would indicate that clinical trial cancellations have troughed and software demand is accelerating, narrowing the gap between market price $258.21 and Fair value $215.19.
In-line
Maintain Reduce; Maintain defensive underweight positioning and continue trimming into strength above Fair value.
Trigger: Consolidated financial performance matching consensus estimates with stable trial delivery and recurring software subscription renewals.
Meeting consensus targets confirms our thesis that revenue growth is steady but insufficient to justify the premium over $215.19, given balance sheet debt obligations.
Industry capex-to-revenue stands at 4.5% and capex-to-depreciation is 0.8x, indicating disciplined reinvestment below depreciation rates following the pandemic-era expansion boom. Because capacity, supply, lead-time, and customer-concentration evidence is unavailable in the reported dataset, this cycle view is demand-led and evidence-limited.
Bull cycle
Acceleration in global biopharma R&D budgets, surging venture funding for mid-sized biotech, and rapid expansion of complex Phase II/III clinical trial protocols driving double-digit net bookings and operating leverage.
Bear cycle
Prolonged biotechnology funding winter, trial cancellations, sponsor pipeline reprioritization, and site coordinator wage inflation squeezing operating margins below 11%.
§11 Position management
Sizing
0-1%
Under our Reduce rating, we recommend an underweight allocation of 0-1% of portfolio assets. The stock trades at $258.21, a 20.0% premium over house Fair value of $215.19. Given $16,174M in total debt and upcoming refinancing requirements at 6.41% pre-tax yields, capital preservation warrants trimming positions.2,4
Risk
Portfolio risk management requires sizing IQVIA defensively due to the asymmetry between high leverage and moderate cash flow yields. While IQVIA maintains strong operating cash flow of $2,654M, net debt of $14,033M ($16,174M total debt less $1,980M cash), leaves the equity highly sensitive to refinancing rates and biopharma trial volumes. Investors should enforce strict exit discipline, utilizing trailing stops and trimming into strength toward $265.00-$275.00.
§12 Investor perspectives
Institutional Investor
Avoid
IQVIA was priced at $258.21 on October 2, 2026, trading at a 19.99% premium over our Fair value of $215.19. Heavy balance sheet debt of $16,174M provides an unfavorable risk-reward profile for core institutional portfolios.4
Value Investor
Avoid
IQVIA pays no dividend and trades at a substantial premium to our Fair value of $215.19. Maturing debt of $7,413M through 2028 at a 6.41% pre-tax borrowing cost limits share repurchase power and provides no value margin of safety.2
Growth Investor
Avoid
While consensus projects FY2027 diluted EPS of $14.47, revenue growth has moderated to mid-single digits (6.79% in FY2026). The report-date price of $258.21 exceeds our of $256.27, leaving no upside potential.
§14 Final recommendation
Action
Reduce
We recommend reducing exposure to IQVIA Holdings Inc.. The stock was priced at $258.21 on October 2, 2026, trading at a 19.99% premium over our fundamental Fair value of $215.19. Elevated balance sheet leverage with $16,174M in total debt and $7,413M in debt maturing within three years will raise interest expenses in a 5.24% risk-free rate environment, constraining future share buybacks.2,4,6
While IQVIA maintains an insulated competitive moat in clinical trial management ($8,896M FY2025 revenue) and proprietary healthcare data ($6,626M revenue), stagnated at 13.38% in FY2025 due to site wage inflation. Even under constructive growth scenarios, is capped at $256.27, offering no upside from the report-date price of $258.21.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 chars
Sources
The records this analysis drew on, as they stood when it was run.
Analyst consensusData as of 2026-10-03 · Published 2026-10-03 · Provider-adjusted · cited for 2 figuresCited in Bear case, Investor perspectives
Market and peer researchData as of 2026-10-03 · Published 2026-10-03 · Provider-adjusted · cited for 2 figuresCited in Competitive moat, Financial history
Consolidated revenue growth decelerates sharply as clinical study start dates are deferred by budget-constrained sponsors
Operating margin compresses significantly due to persistent trial site labor wage pressures and pricing concessions
High refinancing borrowing costs force the complete suspension of share buybacks to service approaching debt maturities
The Bear scenario models a downside operating environment where prolonged funding constraints across emerging biopharmaceutical sponsors trigger clinical trial cancellations and study postponements. At the same time, persistent wage inflation for clinical trial site coordinators compresses operating profitability, while elevated corporate borrowing yields increase annual debt servicing obligations on upcoming debt maturities. Share repurchases are curtailed to preserve liquidity, leading to slower per-share earnings growth and valuation multiple contraction.
Ways this thesis can break
Persistent clinical trial wage inflation and contract pricing resistance in biopharma procurement compress consolidated operating margin by 300 bps across the forecast horizon.
Consolidated operating income was $2,182M on $16,310M revenue (13.38% operating margin) in FY2025, while gross margin compressed from 34.89% to 33.29%. Site coordinator wage inflation and customer procurement concessions in R&D Solutions ($8,896M revenue) create severe margin compression risk. If operating margin drops to 10.38% within 18 months, fair value would decline by 24.5%.6,7
FV impact
-3.2%
Operating margin 3 points lower throughout
Trigger
Within 18 months
Prolonged venture capital contraction across emerging biotech triggers widespread Phase II/III trial cancellations, cutting top-line revenue growth by 5 percentage points annually across the 5-year forecast.
R&D Solutions represents 54.5% of revenue ($8,896M in FY2025). Consensus currently projects 6.79% top-line growth in FY2026. Prolonged biopharma funding constraints directly trigger study start postponements and protocol cancellations, lowering annual growth to 1.79% over a 24-month horizon and reducing fair value by 31.5%.7
FV impact
-4.8%
Revenue and EPS growth 5 points lower for five years
Trigger
Within 24 months
Early-warning signals to monitor
The five developments that would weaken our investment case.
01
R&D Solutions Net Book-to-Bill Ratio
Signals biopharma trial cancellations and postponements outstripping new trial bookings, directly impairing the multi-year revenue backlog and forcing top-line deceleration in R&D Solutions ($8,896M FY2025 revenue).
Indicates persistent site coordinator wage inflation and customer procurement concessions in clinical trials that cannot be offset by software delivery in Technology & Analytics Solutions,.
Reflects growing debt service strain on $16,174M total debt with $7,413M maturing within three years at a pre-tax cost of debt of 6.41%, forcing a complete suspension of share buybacks to preserve liquidity,,.
Current:5.29x ($14,033M net debt on $2,654M OCF in FY2025)
Signals biopharma commercial analytics budget cuts or data licensing churn in Technology & Analytics Solutions ($6,626M revenue in FY2025), eliminating the primary driver of corporate operating margin expansion.
Despite these formidable operational barriers, IQVIA's moat rating is bounded at narrow due to balance sheet structure and service cost economics. The latest ROIC of 9.11% exceeds the computed WACC of 8.525%, generating a modest economic profit spread of 58 bps. However, returns on capital are dampened by $16,616M of historical merger goodwill and $16,174M of total debt. Unlike life sciences tools peers (Agilent, Danaher) that achieve gross margins of 53.6% to 58.8% through proprietary instruments, IQVIA's gross margin of 33.29% reflects heavy labor pass-through expenses in clinical trial execution, capping long-run return durability.
With a computed WACC of 8.525% against an ROIC of 9.11%, IQVIA sustains a positive return spread of 58 bps that validates its narrow moat rating. While reported invested capital remains weighed down by $16,616M of historical merger goodwill, the company's entrenched clinical trial workflows and syndicated health data assets generate sufficient economic rents to maintain returns above capital costs over a multi-year horizon.2
7.8/ 10
Narrow
Sources of advantage
01High Customer Switching Costs in Clinical Trial Execution — Biopharmaceutical sponsors face immense regulatory, procedural, and operational switching barriers once trial protocols, clinical investigator sites, and patient recruitment workflows are contracted with IQVIA. R&D Solutions accounts for $8,896M or 54.5% of FY2025 revenue, supported by multi-year backlog and global presence across the Americas ($7,745M), EMEA ($5,185M), and APAC ($3,380M),,.Wide
02Intangible Assets and Proprietary Health Data Network — Technology & Analytics Solutions ($6,626M revenue in FY2025, 40.6% share) controls proprietary longitudinal healthcare data, syndicated prescription tracking, and commercial software assets deeply embedded in pharmaceutical commercialization and regulatory reporting workflows.Wide
03Global Scale Advantage in Multi-Center Clinical Infrastructure — IQVIA's global investigator network and clinical monitoring footprint enable rapid patient recruitment and multi-jurisdiction regulatory compliance across 100+ countries, creating scale barriers that smaller contract research organizations cannot replicate without extensive capital outlays,.Moderate
Biopharma Sponsor In-Sourcing and Procurement Cost Containment
medium
12-36 months
IQVIA counters procurement scrutiny by integrating real-world evidence and AI trial optimization tools from Technology & Analytics Solutions into R&D Solutions contracts to lower overall trial execution costs.7
Regulatory Restrictions on Healthcare Data Monetization and Privacy Compliance
low
24-48 months
Proprietary privacy-enhancing technologies and patented tokenization allow IQVIA to process de-identified longitudinal patient records in strict compliance with HIPAA and GDPR standards.7
Investigator Site Coordinator Wage Inflation and Pass-Through Margin Squeeze
medium
12-24 months
Management employs automated remote clinical monitoring platforms and decentralized trial methodologies to control personnel hours per protocol.6
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Revenue compounds at mid-single-digit rates across the forecast horizon, matching consensus expectations for FY2026 and FY2027
Operating margin expands modestly from historical baselines as software delivery offsets clinical site personnel inflation
Free cash flow conversion remains solid, supporting disciplined share repurchases and orderly debt service
The Base scenario reflects the modal operating path where clinical trial execution compounds at steady mid-single-digit rates, supported by multi-year trial commitments across global pharmaceutical sponsors. Technology and Analytics Solutions delivers predictable recurring revenue from proprietary syndicated prescription databases and enterprise commercial software. Operating margins expand modestly as high-margin data products gradually offset clinical site coordinator wage pressures. The house Fair value $215.19 corresponds to this trajectory, indicating -16.7% implied return from the share price $258.21 with an assigned probability of 65.0%.
Under the Bull scenario, robust biopharmaceutical venture funding accelerates Phase II and Phase III trial starts, driving double-digit net bookings in clinical research. Simultaneously, rapid adoption of artificial intelligence tools and real-world evidence platforms in commercial analytics accelerates revenue expansion and pushes operating margins toward the upper end of historical ranges. Robust cash generation enables sustained share count reduction while debt is steadily paid down. The stock reaches Potential value $256.27 under this outcome, representing -0.8% return from the share price $258.21 with a probability of 15.0%.
Downgrade the rating; Accelerate reduction of holdings and execute capital preservation measures.
Trigger: Consolidated revenue or operating margin falling short of expectations due to delayed trial starts, elevated cancellations, or higher site coordinator wage expenses.
A quarterly shortfall would demonstrate that biopharma budget constraints are directly impairing clinical trial execution, pushing intrinsic valuation toward downside levels.
Earnings quality is supported by healthy cash conversion where operating cash flow substantially exceeds GAAP net income, reflecting the asset-light nature of clinical trial orchestration and software delivery. Receivables collection remains aligned with multi-quarter master service agreements across major biopharmaceutical clients, and stock-based compensation remains a modest fraction of consolidated revenue. However, gross margin compression reflects rising clinical site personnel expenses and pass-through costs that require ongoing monitoring.
Metrics to watch into the print
01
Metric:
R&D Solutions Net Book-to-Bill Ratio
CurrentTracking comfortably above parity, supported by sustained multi-year clinical trial backlog commitments from global pharmaceutical sponsors.
Why it matters
Measures net new clinical trial business booked relative to revenue recognized; a sustained ratio above parity signals healthy backlog expansion and ensures multi-year revenue visibility, whereas a drop reveals trial cancellations or delays that would reduce future earnings per share.
02
Metric:
Technology and Analytics Solutions Organic Revenue Growth
CurrentDemonstrating steady mid-single-digit expansion, backed by multi-year enterprise renewals and real-world evidence analytics demand.
Why it matters
High-margin commercial software and proprietary data licensing drive corporate operating margin expansion; acceleration reveals deepening client adoption of real-world evidence platforms, lifting consolidated profitability and cash flow.
CurrentFacing moderate pressure from investigator site wage inflation and pass-through costs in clinical trial delivery.
Why it matters
Reflects the balance between high-margin analytics delivery and clinical site coordinator wage inflation; margin expansion expands operating profit and free cash flow conversion, while margin compression reduces capital return capacity.
CurrentRobust conversion driven by low capital expenditure requirements across data infrastructure and clinical service management.
Why it matters
Determines the internal liquidity available for debt reduction and share repurchases after satisfying capital expenditures; strong conversion protects balance sheet flexibility under restrictive credit conditions.
05
Metric:
Effective Borrowing Cost on Debt Refinancing
CurrentElevated due to higher benchmark treasury yields and prevailing corporate credit spreads across intermediate debt maturities.
Why it matters
With substantial maturities approaching across the intermediate forecast, the effective interest rate achieved on replacement debt determines net interest expense, directly impacting net income and diluted earnings per share.
Capital allocation is heavily skewed toward share repurchases and debt service. In FY2025, the company deployed $1,244M into share repurchases, driving diluted shares outstanding down from historical levels toward 173.5M. However, total debt of $16,174M against cash of $1,980M leaves net debt at $14,033M. With $7,413M in debt maturities due within three years and pre-tax debt costs at 6.41%, capital allocation discipline requires shifting free cash flow toward balance sheet deleveraging rather than sustained share buybacks.
IQVIA's ROIC is structurally weighed down by $16,616M of historical merger goodwill. On an operational tangible capital basis, the core CRO and software platforms deliver high cash earnings, but the heavy balance sheet and debt burden ($16,174M total debt) mean economic value creation remains modest relative to the cost of capital.
Latest ROIC of 9.11% exceeds computed WACC of 8.525%, generating a modest positive economic return spread of 58 bps.
High Free Cash Flow Conversion Masks Stagnant GAAP Operating Profit
Without top-line reacceleration or pricing power over investigator site inflation, earnings growth will rely entirely on financial engineering and buybacks rather than organic operational expansion.
Debt Maturity Wall Creates Interest Expense Headwind in Higher-for-Longer Environment
Total debt stands at $16,174M, with $7,413M (50.3%) maturing within three years, compared to cash of $1,980M and a pre-tax borrowing cost of 6.41%.
R&D Solutions ($8,896M revenue, 54.5% of total) is subject to labor pass-through costs, while Technology & Analytics Solutions ($6,626M revenue, 40.6% of total) carries higher margins.
Because clinical trial execution dominates the revenue mix, corporate operating margins will remain structurally constrained between 13.5% and 14.7%, well below life sciences tools peers (Agilent at 25.56%).
IQVIA Holdings Inc. (IQV) trades at 18.4x forward earnings against a peer median of 27.9x. Its EV/EBITDA of 18.6x compares with a peer median of 24.8x. The comparison uses 4 peers: Illumina Inc., IDEXX Laboratories Inc., Agilent Technologies Inc. and Danaher Corporation, as of 2026-10-03.
Secular trends
Trend
Impact
Note
Outsourcing of Biopharmaceutical Clinical Research
positive
Pharmaceutical sponsors increasingly outsource complex Phase I-IV trials to global CROs to convert fixed research overhead into variable costs, supporting steady demand for R&D Solutions ($8,896M FY2025 revenue).
Proliferation of Real-World Evidence and AI-Driven Health Analytics
positive
Regulatory bodies and healthcare payors increasingly demand longitudinal patient outcomes and post-marketing surveillance data, driving multi-year demand for Technology & Analytics Solutions ($6,626M FY2025 revenue).
Early-Stage Biotechnology Funding Normalization and Capital Discipline
negative
Higher cost of capital for emerging biopharma limits speculative trial starts, creating booking conversion headwinds and pricing scrutiny during sponsor contract negotiations.
Positioning
IQVIA is positioned as an indispensable counter-cyclical partner for biopharma sponsors seeking to optimize trial spend and accelerate regulatory submissions, though its $16,174M debt burden reduces capital flexibility relative to debt-free instrument peers.4
Entry tranches
Level
Action
Why
Above $230.00
Hold / Stand Aside
Shares trade at an unwarranted premium to Fair value of $215.19; maintain underweight stance and avoid adding exposure.
At or below Fair Value of $215.19
Re-evaluate for Neutral Allocation
Reaching our Fair value mid of $215.19 eliminates the current 20.0% valuation premium, creating a balanced risk-reward profile conditional on stable clinical trial bookings.
Downgrade stance to Sell and accelerate liquidation of residual position, as backlog conversion slowdown directly impairs forward revenue compounding.7
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Discounted forecast-period cash flows ($46.60) plus discounted terminal value ($175) minus signed net debt per current share ($85.26) equals the $137 lens value shown above. Negative net debt is net cash, so subtracting it raises value.
